MUFG Americas Holdings Corp trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 194,666 shares of the biopharmaceutical company’s stock after selling 4,922 shares during the period. MUFG Americas Holdings Corp’s holdings in Gilead Sciences were worth $13,790,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the company. Archford Capital Strategies LLC acquired a new position in Gilead Sciences during the first quarter worth about $106,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in Gilead Sciences during the second quarter worth about $132,000. Brand Asset Management Group Inc. acquired a new position in Gilead Sciences during the second quarter worth about $139,000. Advisors Preferred LLC acquired a new position in Gilead Sciences during the first quarter worth about $140,000. Finally, Stelac Advisory Services LLC acquired a new position in Gilead Sciences during the first quarter worth about $141,000. 78.01% of the stock is currently owned by institutional investors.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at approximately $238,825,271.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.30% of the company’s stock.

GILD has been the topic of a number of research analyst reports. Morgan Stanley lifted their target price on Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a report on Thursday, July 26th. Mizuho reaffirmed a “buy” rating and set a $94.00 target price on shares of Gilead Sciences in a report on Friday, August 10th. Raymond James initiated coverage on Gilead Sciences in a report on Thursday, June 28th. They set a “strong-buy” rating and a $93.00 target price on the stock. Wells Fargo & Co lifted their target price on Gilead Sciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Finally, Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Wednesday, July 18th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $88.00.

NASDAQ:GILD opened at $76.29 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 3.00 and a quick ratio of 2.92. Gilead Sciences, Inc. has a 1-year low of $64.27 and a 1-year high of $89.54. The firm has a market capitalization of $97.13 billion, a P/E ratio of 8.91, a P/E/G ratio of -5.71 and a beta of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The business had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter last year, the company posted $2.56 EPS. Gilead Sciences’s revenue for the quarter was down 20.9% on a year-over-year basis. research analysts expect that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 27th. Investors of record on Friday, September 14th will be given a $0.57 dividend. The ex-dividend date is Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.99%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Hedge Funds – How They Work For Investors

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.